[Form 4] Jazz Pharmaceuticals, Inc. Insider Trading Activity
Seamus Mulligan, a director of Jazz Pharmaceuticals (JAZZ), was granted 3,507 restricted stock units on 08/07/2025. Each unit represents a contingent right to one ordinary share and, subject to continuous service and plan conditions, the units will vest in full on July 24, 2026.
Following the reported transaction, the filing shows the reporting person beneficially owns 1,179,613 shares directly and 101,621 shares indirectly through Nerano Pharma Limited, an entity owned and controlled by the reporting person and his immediate family. The grant was made under the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan.
Seamus Mulligan, membro del consiglio di Jazz Pharmaceuticals (JAZZ), ha ricevuto 3,507 unit脿 azionarie vincolate il 08/07/2025. Ciascuna unit脿 rappresenta il diritto condizionato a una azione ordinaria e, subordinatamente alla continuit脿 del servizio e alle condizioni del piano, le unit脿 matureranno integralmente il 24 luglio 2026.
A seguito dell'operazione riportata, la denuncia indica che la persona che informa detiene beneficiariamente 1,179,613 azioni direttamente e 101,621 azioni indirettamente tramite Nerano Pharma Limited, una entit脿 posseduta e controllata dalla persona che informa e dai suoi familiari diretti. La concessione 猫 avvenuta ai sensi del Piano di Assegnazione di Azioni per Amministratori Non Esecutivi del 2007, emendato e riformulato dell'Emittente.
Seamus Mulligan, miembro del consejo de Jazz Pharmaceuticals (JAZZ), recibi贸 3,507 unidades de acciones restringidas el 08/07/2025. Cada unidad representa un derecho contingente a una acci贸n ordinaria y, sujeto a la prestaci贸n continua de servicios y a las condiciones del plan, las unidades se consolidar谩n en su totalidad el 24 de julio de 2026.
Tras la operaci贸n comunicada, la presentaci贸n muestra que la persona informante posee beneficiariamente 1,179,613 acciones de forma directa y 101,621 acciones de forma indirecta a trav茅s de Nerano Pharma Limited, una entidad de la que la persona informante y su familia inmediata son propietarios y la controlan. La adjudicaci贸n se realiz贸 en el marco del Plan de Asignaci贸n de Acciones para Directores No Ejecutivos de 2007, enmendado y reformulado, del emisor.
Jazz Pharmaceuticals (JAZZ) 鞚挫偓鞚� Seamus Mulligan鞐愱矊 2025/08/07鞐� 3,507臧滌潣 鞝滍暅欤检嫕雼渼(RSUs)臧� 攵�鞐悩鞐堨姷雼堧嫟. 臧� 雼渼電� 氤错喌欤� 1欤检棎 雽�頃� 臁瓣贝攵� 甓岆Μ毳� 鞚橂頃橂┌, 歆�靻嶌爜鞚� 攴茧 氚� 頂岆灉 臁瓣贝鞚� 於╈”霅橂姅 瓴届毎 頃措嫻 雼渼電� 2026雲� 7鞗� 24鞚检棎 鞝勲秬 頇曥爼霅╇媹雼�.
氤搓碃霅� 瓯半灅 頉� 鞝滌稖霅� 靹滊鞐� 霐半ゴ氅�, 氤搓碃鞚胳潃 歆侅爲鞝侅溂搿� 1,179,613欤茧ゼ, Nerano Pharma Limited毳� 韱淀暣 臧勳爲鞝侅溂搿� 101,621欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. Nerano Pharma Limited電� 氤搓碃鞚戈臣 攴胳潣 歆侁硠 臧�臁膘澊 靻岇湢路甏�毽晿電� 氩曥澑鞛呺媹雼�. 鞚措矆 攵�鞐姅 氚滍枆須岇偓鞚� 2007雲� 臧滌爼路鞛爼牍勲悳 牍勳瀯鞗� 鞚挫偓 欤检嫕 靾橃棳 瓿勴殟鞐� 霐半澕 鞚措（鞏挫鞀惦媹雼�.
Seamus Mulligan, administrateur de Jazz Pharmaceuticals (JAZZ), s'est vu attribuer 3,507 unit茅s d'actions restreintes le 08/07/2025. Chaque unit茅 repr茅sente un droit conditionnel portant sur une action ordinaire et, sous r茅serve de la continuit茅 du service et des conditions du plan, ces unit茅s deviendront pleinement acquises le 24 juillet 2026.
脌 la suite de la transaction d茅clar茅e, le dossier indique que la personne d茅clarante d茅tient 脿 titre b茅n茅ficiaire 1,179,613 actions directement et 101,621 actions indirectement via Nerano Pharma Limited, une entit茅 d茅tenue et contr么l茅e par la personne d茅clarante et sa famille proche. L'attribution a 茅t茅 effectu茅e en vertu du Plan d'attribution d'actions aux administrateurs non ex茅cutifs de 2007, amend茅 et refondu, de l'茅metteur.
Seamus Mulligan, Direktor von Jazz Pharmaceuticals (JAZZ), wurde am 08/07/2025 eine Zuteilung von 3,507 Restricted Stock Units gew盲hrt. Jede Einheit entspricht dem bedingten Anspruch auf eine Stammaktie und unterliegt der fortlaufenden Dienstleistung sowie den Bedingungen des Plans; die Einheiten werden am 24. Juli 2026 vollst盲ndig zuteilungsreif.
Nach der gemeldeten Transaktion weist die Meldung aus, dass die meldende Person wirtschaftlich 1,179,613 Aktien direkt und 101,621 Aktien indirekt 眉ber Nerano Pharma Limited h盲lt, eine Einheit, die von der meldenden Person und deren n盲chster Familie gehalten und kontrolliert wird. Die Zuteilung erfolgte im Rahmen des 2007 眉berarbeiteten und neu gefassten Aktienzuteilungsplans f眉r nicht-gesch盲ftsf眉hrende Direktoren des Emittenten.
- 3,507 restricted stock units granted to a director under the company鈥檚 non-employee directors plan, linking pay to shareholder value.
- Substantial disclosed ownership: 1,179,613 shares held directly and 101,621 shares held indirectly via Nerano Pharma Limited, improving transparency.
- None.
Insights
TL;DR: Director received routine RSU award; significant reported direct and indirect holdings clarify insider stake.
The Form 4 documents a standard non-employee director equity award of 3,507 restricted stock units that convert one-for-one to ordinary shares upon vesting. The filing quantifies the reporting person鈥檚 stake as 1,179,613 shares direct plus 101,621 shares indirect, held by Nerano Pharma Limited. For investors, this clarifies current insider ownership levels and the timeline for potential share issuance tied to vesting on July 24, 2026.
TL;DR: Award aligns director incentives with shareholders; vesting is conditional, maintaining retention incentive.
The award was granted under the company鈥檚 non-employee directors plan, creating alignment through equity compensation. Vesting is contingent on continued service and specified conditions, with full vesting scheduled for July 24, 2026. The filing also discloses indirect ownership via an entity controlled by the director and immediate family, which is important for transparency in related-party ownership disclosures.
Seamus Mulligan, membro del consiglio di Jazz Pharmaceuticals (JAZZ), ha ricevuto 3,507 unit脿 azionarie vincolate il 08/07/2025. Ciascuna unit脿 rappresenta il diritto condizionato a una azione ordinaria e, subordinatamente alla continuit脿 del servizio e alle condizioni del piano, le unit脿 matureranno integralmente il 24 luglio 2026.
A seguito dell'operazione riportata, la denuncia indica che la persona che informa detiene beneficiariamente 1,179,613 azioni direttamente e 101,621 azioni indirettamente tramite Nerano Pharma Limited, una entit脿 posseduta e controllata dalla persona che informa e dai suoi familiari diretti. La concessione 猫 avvenuta ai sensi del Piano di Assegnazione di Azioni per Amministratori Non Esecutivi del 2007, emendato e riformulato dell'Emittente.
Seamus Mulligan, miembro del consejo de Jazz Pharmaceuticals (JAZZ), recibi贸 3,507 unidades de acciones restringidas el 08/07/2025. Cada unidad representa un derecho contingente a una acci贸n ordinaria y, sujeto a la prestaci贸n continua de servicios y a las condiciones del plan, las unidades se consolidar谩n en su totalidad el 24 de julio de 2026.
Tras la operaci贸n comunicada, la presentaci贸n muestra que la persona informante posee beneficiariamente 1,179,613 acciones de forma directa y 101,621 acciones de forma indirecta a trav茅s de Nerano Pharma Limited, una entidad de la que la persona informante y su familia inmediata son propietarios y la controlan. La adjudicaci贸n se realiz贸 en el marco del Plan de Asignaci贸n de Acciones para Directores No Ejecutivos de 2007, enmendado y reformulado, del emisor.
Jazz Pharmaceuticals (JAZZ) 鞚挫偓鞚� Seamus Mulligan鞐愱矊 2025/08/07鞐� 3,507臧滌潣 鞝滍暅欤检嫕雼渼(RSUs)臧� 攵�鞐悩鞐堨姷雼堧嫟. 臧� 雼渼電� 氤错喌欤� 1欤检棎 雽�頃� 臁瓣贝攵� 甓岆Μ毳� 鞚橂頃橂┌, 歆�靻嶌爜鞚� 攴茧 氚� 頂岆灉 臁瓣贝鞚� 於╈”霅橂姅 瓴届毎 頃措嫻 雼渼電� 2026雲� 7鞗� 24鞚检棎 鞝勲秬 頇曥爼霅╇媹雼�.
氤搓碃霅� 瓯半灅 頉� 鞝滌稖霅� 靹滊鞐� 霐半ゴ氅�, 氤搓碃鞚胳潃 歆侅爲鞝侅溂搿� 1,179,613欤茧ゼ, Nerano Pharma Limited毳� 韱淀暣 臧勳爲鞝侅溂搿� 101,621欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. Nerano Pharma Limited電� 氤搓碃鞚戈臣 攴胳潣 歆侁硠 臧�臁膘澊 靻岇湢路甏�毽晿電� 氩曥澑鞛呺媹雼�. 鞚措矆 攵�鞐姅 氚滍枆須岇偓鞚� 2007雲� 臧滌爼路鞛爼牍勲悳 牍勳瀯鞗� 鞚挫偓 欤检嫕 靾橃棳 瓿勴殟鞐� 霐半澕 鞚措（鞏挫鞀惦媹雼�.
Seamus Mulligan, administrateur de Jazz Pharmaceuticals (JAZZ), s'est vu attribuer 3,507 unit茅s d'actions restreintes le 08/07/2025. Chaque unit茅 repr茅sente un droit conditionnel portant sur une action ordinaire et, sous r茅serve de la continuit茅 du service et des conditions du plan, ces unit茅s deviendront pleinement acquises le 24 juillet 2026.
脌 la suite de la transaction d茅clar茅e, le dossier indique que la personne d茅clarante d茅tient 脿 titre b茅n茅ficiaire 1,179,613 actions directement et 101,621 actions indirectement via Nerano Pharma Limited, une entit茅 d茅tenue et contr么l茅e par la personne d茅clarante et sa famille proche. L'attribution a 茅t茅 effectu茅e en vertu du Plan d'attribution d'actions aux administrateurs non ex茅cutifs de 2007, amend茅 et refondu, de l'茅metteur.
Seamus Mulligan, Direktor von Jazz Pharmaceuticals (JAZZ), wurde am 08/07/2025 eine Zuteilung von 3,507 Restricted Stock Units gew盲hrt. Jede Einheit entspricht dem bedingten Anspruch auf eine Stammaktie und unterliegt der fortlaufenden Dienstleistung sowie den Bedingungen des Plans; die Einheiten werden am 24. Juli 2026 vollst盲ndig zuteilungsreif.
Nach der gemeldeten Transaktion weist die Meldung aus, dass die meldende Person wirtschaftlich 1,179,613 Aktien direkt und 101,621 Aktien indirekt 眉ber Nerano Pharma Limited h盲lt, eine Einheit, die von der meldenden Person und deren n盲chster Familie gehalten und kontrolliert wird. Die Zuteilung erfolgte im Rahmen des 2007 眉berarbeiteten und neu gefassten Aktienzuteilungsplans f眉r nicht-gesch盲ftsf眉hrende Direktoren des Emittenten.
FAQ
What securities transaction did Seamus Mulligan report on Form 4 for JAZZ?
When will the granted restricted stock units vest?
How many Jazz Pharmaceuticals shares does the reporting person beneficially own after the transaction?
What is Nerano Pharma Limited's relationship to the reporting person?
Under which plan were the restricted stock units granted?
